logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 14 of 14 Items
Showing 1 - 14 of 14 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A,  et al.
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Journal Article
|
Research

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|
Short Report

Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan PY, Franke MF, Ahmed SM, Aiylchiev S,  et al.
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Journal Article
|
Research

Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

Seung KJ, Khan P, Franke MF, Ahmed S, Aiylchiev S,  et al.
2020-07-11 • Clinical Infectious Diseases
2020-07-11 • Clinical Infectious Diseases

Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observati...

Journal Article
|
Research

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Journal Article
|
Commentary

Introducing new and repurposed TB drugs: the endTB experience

Seung KJ, Khan UT, Varaine FFV, Ahmed SM, Bastard M,  et al.
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
In 2015, the initiative Expand New Drug Markets for TB (endTB) began, with the objective of reducing barriers to access to the new and repurposed TB drugs. Here we describe the major imp...
Journal Article
|
Research

High prevalence of infection and low incidence of disease in child contacts of patients with drug-resistant tuberculosis: a prospective cohort study

Huerga H, Sanchez-Padilla E, Melikyan N, Atshemyan H, Ulumyan A,  et al.
2018-12-06 • Archives of Disease in Childhood
2018-12-06 • Archives of Disease in Childhood
OBJECTIVE
We aimed to measure the prevalence and incidence of latent tuberculosis infection (LTBI) and tuberculosis (TB) disease in children in close contact with patients with drug-...
Journal Article
|
Research

Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study

Ferlazzo G, Mohr E, Laxmeshwar C, Hewison CCH, Hughes J,  et al.
2018-02-13 • Lancet Infectious Diseases
2018-02-13 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...
Journal Article
|
Letter

Bedaquiline and Repurposed Drugs for Fluoroquinolone-Resistant MDR-TB: How Much Better Are They?

Bastard M, Guglielmetti L, Huerga H, Hayrapetyan A, Khachatryan N,  et al.
2018-07-03 • American Journal of Respiratory and Critical Care Medicine
2018-07-03 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Research

Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis

Mbuagbaw L, Guglielmetti L, Hewison CCH, Bakare N, Bastard M,  et al.
2019-05-01 • Emerging Infectious Diseases
2019-05-01 • Emerging Infectious Diseases
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 c...
Journal Article
|
Research

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

Hewison CCH, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A,  et al.
2018-07-01 • International Journal of Tuberculosis and Lung Disease
2018-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.

OBJECTIVE
To assess the effectiveness and safety of multidrug...
Technical Report
|
Study report

endTB interim analysis report - Bedaquiline- and delaminid- containing regimens achieve excellent interim treatment response without safety concerns

Atwood S, Avagyan N, Bastard M, Cain M, Collin S,  et al.
2018-07-01
2018-07-01
Conference Material
|
Poster

Hepatitis C and multidrug resistant tuberculosis co-morbidities: no longer an untreatable combination

Khachatryan N, Sargsynats N, Balkan S, Bastard M, Huerga H,  et al.
2018-05-20 • MSF Scientific Days International 2018: Research
2018-05-20 • MSF Scientific Days International 2018: Research
Journal Article
|
Research

Concomitant treatment of chronic hepatitis C with direct-acting antivirals and multidrug-resistant tuberculosis is effective and safe

Melikyan N, Huerga H, Atshemyan H, Kirakosyan O, Sargsyants N,  et al.
2021-01-04 • Open Forum Infectious Diseases
2021-01-04 • Open Forum Infectious Diseases
We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 M...